B-FAST faciliteert de ontwikkeling van vaccins tegen het Bundibugyo ebolavirus in DRC
B-FAST facilitates the development of vaccines against the Bundibugyo Ebola virus in the DRC lien.horemans Thu, 10/29/2026 - 13:42 News Type Press release Countries Democratic Republic of the Congo Subjects B-FAST PB B-FAST Last updated on October 29, 2026 Since the Bundibugyo Ebola outbreak was confirmed in May 2026 in the Democratic Republic of the Congo (DRC), Belgium has been closely monitoring the situation. As part of this effort, our country is supporting research into vaccines and treatments, among other initiatives. In this context, a large-scale clinical trial recently began in Bunia (DRC), coordinated by the Congolese Institut National de Recherche Biomédicale (INRB) and the Global Health Institute at the University of Antwerp, and conducted by an international consortium of partners. The Institute of Tropical Medicine in Antwerp (ITM) is leading the laboratory activities, the analysis of immune responses following vaccination, and the social science research into factors that may influence participation in clinical trials and the subsequent rollout of vaccines. To support these scientific efforts, the Ministry of Defence, through B-FAST, is providing an A400M transport
Plan Gratis · Plus 29 CA$ o Pro 99 CA$/mes


